EGFR G465R

CI-VAR-00001743Explore in graph →NP_005219.2:p.Gly465ArgNM_005228.3:c.1393G>AClinVar 2011745 CIViC 443 rs2128941520

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm3
EGFR G465R	Cetuximab + PanitumumabSubstitutes	Predictive	B	Supports Resistance	3	submitted	EID7083 Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC) PMID 29196463 · Strickler et al., 2018 · Open in CIViC	civic
EGFR G465R	Cetuximab + PanitumumabSubstitutes	Predictive	C	Supports Resistance	4	accepted	EID1058 An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
2011745	Uncertain significance	criteria provided, single submitter	1	EGFR-related lung cancer	germline	1	Dec 01, 2025	clinvar